|
EA037918B1
(ru)
|
2011-12-21 |
2021-06-07 |
Новира Терапьютикс, Инк. |
Противовирусные агенты против гепатита в
|
|
HK1208465A1
(en)
|
2012-08-28 |
2016-03-04 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
EP2917184A4
(en)
*
|
2012-11-09 |
2016-06-29 |
Univ Indiana Res & Tech Corp |
ALTERNATIVE USES FOR HBV ARRANGEMENT EFFECTORS
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
WO2014093622A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
DK2961732T3
(en)
|
2013-02-28 |
2017-07-10 |
Janssen Sciences Ireland Uc |
SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
WO2014161888A1
(en)
|
2013-04-03 |
2014-10-09 |
Janssen R&D Ireland |
N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
EP3674411A1
(en)
|
2013-06-17 |
2020-07-01 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
EP3597755A1
(en)
|
2013-06-17 |
2020-01-22 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
|
CA2915837A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
KR20240172759A
(ko)
|
2013-06-17 |
2024-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
간의 표적화 및 치료를 위한 ＣＲＩＳＰＲＣａｓ 시스템, 벡터 및 조성물의 전달 및 용도
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
ES2774749T3
(es)
|
2013-07-25 |
2020-07-22 |
Janssen Sciences Ireland Unlimited Co |
Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
|
|
KR102290189B1
(ko)
|
2013-10-23 |
2021-08-17 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
CN105899658B
(zh)
|
2013-12-12 |
2020-02-18 |
布罗德研究所有限公司 |
针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
WO2015089354A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
EP3653229A1
(en)
|
2013-12-12 |
2020-05-20 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
KR20160128305A
(ko)
|
2014-02-05 |
2016-11-07 |
노비라 테라퓨틱스, 인코포레이티드 |
Hbv 감염의 치료를 위한 병용 요법
|
|
DK3102572T3
(en)
|
2014-02-06 |
2019-02-04 |
Janssen Sciences Ireland Uc |
SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
|
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
|
MX375407B
(es)
*
|
2014-06-20 |
2025-03-06 |
Univ Drexel |
Antígeno e de hepadnavirus marcado y su uso en el tamizado de sustancias antivirales.
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
WO2016149581A1
(en)
|
2015-03-19 |
2016-09-22 |
Novira Therapeutics, Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
|
US10442788B2
(en)
|
2015-04-01 |
2019-10-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
US10738035B2
(en)
|
2015-05-13 |
2020-08-11 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
MX392008B
(es)
|
2015-06-18 |
2025-03-21 |
Broad Inst Inc |
Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
WO2017011552A1
(en)
|
2015-07-13 |
2017-01-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2017015451A1
(en)
*
|
2015-07-22 |
2017-01-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
US10301255B2
(en)
|
2015-07-22 |
2019-05-28 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
KR101771309B1
(ko)
*
|
2015-07-24 |
2017-08-24 |
재단법인 목암생명과학연구소 |
B형 간염 바이러스의 ｃｃｃＤＮＡ 형성 억제용 약학 조성물
|
|
HK1259410A1
(zh)
|
2015-09-29 |
2019-11-29 |
诺维拉治疗公司 |
乙型肝炎抗病毒剂的晶体形式
|
|
US10280175B2
(en)
|
2016-02-02 |
2019-05-07 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
BR112018067964B1
(pt)
|
2016-03-07 |
2024-01-16 |
Enanta Pharmaceuticals, Inc |
Composto, composição farmacêutica que o compreende e uso do referido composto
|
|
EP3442524A2
(en)
|
2016-04-15 |
2019-02-20 |
Novira Therapeutics Inc. |
Combinations and methods comprising a capsid assembly inhibitor
|
|
MX2018015315A
(es)
|
2016-06-10 |
2019-04-25 |
Enanta Pharm Inc |
Agentes antivirales contra la hepatitis b.
|
|
JP7373991B2
(ja)
|
2016-07-15 |
2023-11-06 |
ビラクタ セラピューティクス，インク． |
免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
|
|
EP3556402A4
(en)
*
|
2016-12-13 |
2020-08-05 |
AM Sciences Inc |
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS B
|
|
IL272941B2
(en)
|
2017-08-28 |
2023-03-01 |
Enanta Pharm Inc |
Antiviral agents for viral hepatitis b
|
|
CN112105359B
(zh)
*
|
2017-12-04 |
2023-12-01 |
豪夫迈·罗氏有限公司 |
作为cccDNA抑制剂用于治疗乙型肝炎病毒(HBV)感染的吡咯并[2,3-b]吡嗪化合物
|
|
TW201927789A
(zh)
|
2017-12-06 |
2019-07-16 |
美商因那塔製藥公司 |
B型肝炎抗病毒試劑
|
|
TW201936192A
(zh)
|
2017-12-06 |
2019-09-16 |
美商因那塔製藥公司 |
B 型肝炎抗病毒試劑
|
|
US11058678B2
(en)
|
2018-01-22 |
2021-07-13 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
EA202092171A1
(ru)
|
2018-03-14 |
2020-12-01 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Схема дозирования модулятора сборки капсида
|
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
KR102273071B1
(ko)
*
|
2018-06-12 |
2021-07-05 |
주식회사 에이엠사이언스 |
B형 간염 예방 또는 치료용 조성물
|
|
WO2019240504A1
(en)
*
|
2018-06-12 |
2019-12-19 |
Am Sciences Co., Ltd. |
Modified oligonucleotides for inhibition of target gene expression
|
|
WO2020061435A1
(en)
|
2018-09-21 |
2020-03-26 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
EP3870295B1
(en)
*
|
2018-10-24 |
2023-03-08 |
F. Hoffmann-La Roche AG |
Novel tricyclic compounds for the treatment and prophylaxis of hepatitis b virus disease
|
|
KR102819704B1
(ko)
|
2018-11-21 |
2025-06-11 |
이난타 파마슈티칼스, 인코포레이티드 |
항바이러스제로서의 작용화된 헤테로사이클
|
|
MA55020A
(fr)
|
2019-02-22 |
2021-12-29 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
BR112021021454A2
(pt)
|
2019-05-06 |
2021-12-21 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
|
|
SG11202113215UA
(en)
|
2019-05-31 |
2021-12-30 |
Viracta Subsidiary Inc |
Methods of treating virally associated cancers with histone deacetylase inhibitors
|
|
US11236111B2
(en)
|
2019-06-03 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
US11472808B2
(en)
|
2019-06-04 |
2022-10-18 |
Enanta Pharmaceuticals, Inc. |
Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
|
|
US11760755B2
(en)
|
2019-06-04 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
US11738019B2
(en)
|
2019-07-11 |
2023-08-29 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
WO2021055425A2
(en)
|
2019-09-17 |
2021-03-25 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
JP2022550454A
(ja)
*
|
2019-10-02 |
2022-12-01 |
ユニバーシティ オブ ワシントン |
Ｂ型肝炎ウイルス感染の治療のための組成物及び方法
|
|
WO2021188414A1
(en)
|
2020-03-16 |
2021-09-23 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
JP2023538630A
(ja)
*
|
2020-08-21 |
2023-09-08 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
|
|
CN112274516B
(zh)
*
|
2020-10-26 |
2022-08-05 |
中山大学附属第三医院 |
一种新型含碘抗病毒药物
|
|
IT202100005054A1
(it)
*
|
2021-03-04 |
2022-09-04 |
Azienda Ospedaliero Univ Di Parma |
Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti
|